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ABSTRACT 30 
Sporadic Burkitt lymphoma (sBL) is a rapidly growing B-cell non-Hodgkin’s 31 
lymphoma whose treatment requires highly aggressive therapies that often result 32 
severely toxic. Identification of proteins whose expression or function is deregulated in 33 
sBL and play a role in its formation could facilitate development of less toxic therapies. 34 
We have previously shown that E2F1 expression is deregulated in sBL. We have now 35 
investigated the mechanisms underlying E2F1 deregulation and found that the E2F sites 36 
in its promoter fail to repress its transcriptional activity in BL cells and that the 37 
transcriptional repressor E2F4 barely interacts with these sites. We also have found that 38 
E2F4 protein levels, but not those of its mRNA, are reduced in sBL cell lines relative to 39 
immortal B-cell lines. E2F4 protein expression is also decreased in 24 of 26 sBL tumor 40 
samples from patients compared to control tissues. Our data demonstrate that enforced 41 
E2F4 expression in BL cells not only diminishes E2F1 levels, but also reduces 42 
selectively the tumorigenic properties and proliferation of BL cells, while increasing 43 
their accumulation in G2/M. Our results therefore point to E2F4 as a target for 44 
developing novel and less toxic treatments for sBL. 45 
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INTRODUCTION 50 
Burkitt lymphoma (BL) is a highly aggressive form of mature B-cell non-51 
Hodgkin’s lymphoma. The World Health Organization (WHO) recognizes the existence 52 
of three clinical BL variants: endemic, sporadic, and immunodefficiency-associated (1). 53 
BL is one of the most rapidly growing pediatric tumors, doubling its size every 24 hours 54 
(2), and it is rapidly fatal if untreated. Intensive combination chemotherapy is the 55 
primary treatment for BL together with intrathecal and systemic chemotherapy for 56 
Central Nervous System (CNS) prophylaxis, due to high risk of CNS involvement (3). 57 
Radiation therapy is limited to the treatment of overt CNS disease unresponsive to 58 
chemotherapy and in certain emergencies (3). Unfortunately, the toxicities reported 59 
from these intensive therapies are significant, including neurotoxicities from intrathecal 60 
therapy, hematologic toxicity, severe mucositis, cardiac disease, and infertility (4). The 61 
design of more efficient, more specific, and less toxic therapies relies on the 62 
identification of genes and proteins whose expression or function is affected in BL cells. 63 
Since the etiology of sporadic Burkitt lymphoma (sBL) remains largely unknown, a 64 
better understanding of the molecular mechanisms underlying sBL lymphomagenesis 65 
would undoubtedly help to identify such genes and proteins. 66 
The major pathogenic alteration known to occur in sBL is the translocation of 67 
the C-MYC locus to one of the three different immunoglobulin loci that leads to C-MYC 68 
over-expression (5). However, several studies examining the role of C-MYC in the 69 
pathogenesis of BL have concluded that C-MYC translocation is not the only critical 70 
event (6, 7). In fact, C-MYC over-expression in the absence of additional alterations 71 
elicits either cell death (8) or cell growth arrest in the G2 phase of the cell cycle (9). 72 
Hence, additional factors likely cooperate with C-MYC in BL lymphomagenesis. We 73 
have recently shown that the transcription factor and cell cycle regulator E2F1 is highly 74 
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expressed in 100% of BL cell lines and sBL lymphoma specimens tested so far, relative 75 
to control cell lines and tissues, and that its elevated expression is required for the 76 
formation of this tumor (10).  77 
E2F1 is the founding member of the E2F family of transcription factors. This 78 
family is essential for the regulation of cell growth and play an important role in almost 79 
every phase of the cell cycle (11, 12). Eight different E2F genes (E2F1 to E2F8) and 80 
three different DP genes belong to this family in mammals (13). E2F factors are divided 81 
between transcriptional activators (E2F1, E2F2, and E2F3a) and transcriptional 82 
repressors (E2F3b and E2F4 to E2F8). Transcriptional repression by E2F3b, E2F4 and 83 
E2F5 seems to be dependent upon their association with members of the pocket protein 84 
family that includes the Retinoblastoma protein (pRB), p107 and p130 (14). The 85 
interaction of these proteins with E2F factors not only inhibits E2F-mediated 86 
transactivation (15), but also recruits histone deacetylases and other chromatin-87 
modifying proteins to the promoters of E2F-regulated genes to enforce their active 88 
repression (16). 89 
E2F4 accounts for the majority of E2F proteins throughout the cell cycle (17). In 90 
quiescent cells, E2F4 is primarily nuclear and represses transcription of E2F-regulated 91 
genes through its recruitment of the Retinoblastoma family members p107 and p130 92 
(14). When Retinoblastoma family members are phosphorylated at the end of G1 by 93 
Cyclin-Dependent Kinases (CDKs) in response to mitogens (18, 19), E2F4 unbinds 94 
DNA, dissociates from pocket proteins, and is exported to the cytoplasm (11, 20). Thus, 95 
although E2F4 has a transactivation domain, its transcriptional activity is restrained 96 
because of its interaction with pocket proteins in the nucleus or because of its 97 
translocation to the cytosol when E2F4 is not associated to them (21).  98 
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While E2F factors show bimodal actions in rodent models, functioning either as 99 
oncogenes or as tumor-suppressors (13), it remains largely unknown how E2F family 100 
members affect human tumors. We have recently shown that E2F1 is over-expressed in 101 
sBL and that its deregulated expression is central to the formation of this tumor (10). 102 
However, the precise mechanisms leading to E2F1 over-expression in sBL have not 103 
been identified yet. Here, we show evidence supporting that down-regulation of E2F4 in 104 
sBL prevents repression of the E2F1 promoter, thus leading to increased expression of 105 
E2F1 and tumorigenesis in this lymphoma. Hence, these results point to E2F4 as a 106 
tumor suppressor in sporadic BL. 107 
108 
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MATERIALS AND METHODS 109 
Patients and cells. 110 
All cases consisted of existing frozen de-identified anonymous biopsy specimens 111 
obtained from the Spanish Tumor Bank Network in Centro Nacional de Investigaciones 112 
Oncológicas (CNIO). Institutional review board approval was obtained for these 113 
studies. Biopsy specimens from sBL cases were reviewed by M.A. Piris and S. Montes-114 
Moreno, and characterized according to morphology, C-MYC translocation 115 
identification by Fluorescent in situ hybridization and immunostaining of CD10, BCL2, 116 
BCL6, Ki67, TCL1, and CD44. Cases with atypical Burkitt Lymphoma morphological 117 
features were included only when the rest of phenotypical and cytogenetic criteria were 118 
consistent with a diagnosis of BL, according to the criteria of WHO (1, 22). Twenty-six 119 
specimens corresponding to sBL from patients, together with reactive tonsils were 120 
finally selected. Cases associated with HIV or HCV infections or previous 121 
immunosuppressive treatments were excluded. Representative areas of sixty-seven 122 
specimens corresponding to Diffuse Large B-Cell Lymphoma were selected to construct 123 
tissue microarrays.  124 
BL cell lines DG75, Ramos, Mutu-I, Raji, Rael, Akata, and BL2, as well as 125 
lymphoblastoid B-cell lines (LCL) X50-7, JY, Dana, and IB4, were cultured in RPMI-126 
1640, whereas human embryonic kidney 293-T, human breast cancer MCF-7 and mouse 127 
fibroblasts NIH-3T3 cell lines were cultured in DMEM. Both media were supplemented 128 
with 10% FCS (Life Technologies), 2mM glutamine, 100U/ml penicillin, and 100µg/ml 129 
streptomycin. 130 
Quantitative PCR analysis. 131 
Real-time quantitative RT-PCR (q-PCR) was performed as described (10) using 132 
TaqMan assays specific for human E2F1, E2F4, E2F8 and β-ACTIN (Life 133 
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Technologies). β-ACTIN was chosen as a control gene on the basis of its homogeneous 134 
expression in used cell lines. Calculations were made from measurements of 3 replicates 135 
of each sample. For mRNA stability assays, cell cultures were incubated with the 136 
transcription inhibitor actinomycin D (Sigma-Aldrich). 137 
Transfections and reporter gene assays. 138 
 BL and LCL cells were transfected by electroporation (23). Transfections 139 
included 10µg of pGL2-E2F1-WT or pGL2-E2F1-Null (24) plus either 0.1µg pSV-140 
Renilla and 20µg carrier plasmid [Bluescript (Stratagene)], or 10µg pCEFL-βGal and 141 
10µg carrier plasmid (Bluescript). Firefly and Renilla luciferase activities were assayed 142 
using Dual Luciferase Reporter Assay System (Promega) 48 hours after transfection. ß-143 
galactosidase activity was determined as described (25). Firefly luciferase activity was 144 
normalized with that of Renilla luciferase or that of β-galactosidase. 145 
Preparation of nuclear extracts and electrophoretic mobility shift analysis (EMSA) 146 
assays. 147 
Nuclear extracts were prepared and gel shifts were performed as reported (26) 148 
with labeled oligonucleotides encompassing the distal E2F element from the E2F1 149 
promoter (5´-CTGGAGCTCTTTCGCGGCAAAAAGGAG-3´ and 5´-150 
CAGGCTCCTTTTTGCCGCGAAAGAGCT-3´). Antibodies against E2F4, E2F5, pRB, 151 
p107 and p130 were from Santa Cruz. Anti-DP1 and pre-immune serum were described 152 
(23).   153 
Immunoblotting and immunohistochemistry.  154 
Anti-E2F1, anti-E2F4-E2F6, anti-p130 (all from Santa Cruz), or anti-Tubulin 155 
(Sigma-Aldrich), followed by peroxidase-conjugated anti-rabbit or anti-mouse 156 
antibodies (Sigma-Aldrich) were used. Chemiluminescent detection reagent 157 
(PerkinElmer) was used and the membrane exposed to X-Ray Medical film. For protein 158 
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stability assays, cell cultures were incubated with the transduction inhibitor 159 
cycloheximide (Sigma-Aldrich). 160 
Paraffin-embedded tissue samples and tissue microarrays were stained with anti-161 
E2F4 (GeneTex), anti-p130 (Santa Cruz), or anti-E2F1 (Santa Cruz) and counterstained 162 
with hematoxylin. The specimens were analyzed using an Olympus BX60 microscope 163 
(Olympus Optical). Images were photographed using an Olympus DP50 camera 164 
(Olympus Europe) and Axiovision version 4.6 software (Imaging Associates), and were 165 
adjusted using Adobe Photoshop version 9.0 software (Adobe Systems). 166 
Retrovirus and lentivirus production and infections. 167 
For retrovirus production, human embryonic kidney 293-T cells were co-168 
transfected with pCL-Anfo and either pBabe-puro or pBabe-puro-HA-E2F4 expression 169 
vectors using the calcium-phosphate method (23). Lentiviruses bearing E2F1-specific 170 
shRNAs or scrambled shRNA sequences were produced as described (10) employing 171 
MISSION pLKO.1-puro-based vectors (Sigma-Aldrich) TRCN0000039658 and 172 
SHC002, respectively. Cell transduction was achieved as described (10). Transduced 173 
cells were washed and selected with 1µg/ml puromycin for at least 96 hours.   174 
Cell proliferation and cell cycle analysis.  175 
Cell cycle analysis was performed as described (26). For BL cells, 5 x 104 cells 176 
in 200µl of culture medium were added to each well of a 96-well flat-bottomed 177 
microtiter plate and cultured in triplicate. Cell proliferation was then estimated by 178 
[3H]dThd incorporation (27). NIH-3T3 and MCF-7 cell proliferation was estimated by 179 
EdU incorporation during 16 hours of culture. Cells were harvested and the 180 
incorporated EdU was detected using the Click-iT EdU Alexa fluor 488 Flow 181 
Cytometry Assay Kit (Invitrogen).  182 
Transformation assays in vivo. 183 
  9 
DG75, Mutu-I, or Ramos cells (2 x 106 in 0.1ml of phosphate-buffered saline) 184 
were injected into 8- to 10-week-old female NOD.CB17-Prkdcscid/J mice (Charles River 185 
Laboratories). Tumor masses were removed after 3 weeks and weighted. All animal 186 
procedures were approved by the institutional review board. 187 
Statistical analysis 188 
All values are expressed as means ± S.D. Differences were evaluated using the 189 
Student t test. Statistical significance was assigned at p<0.05. 190 
191 
  10 
RESULTS 192 
Increased E2F1 promoter activity in BL cell lines.  193 
We have previously established that E2F1 levels are higher in sBL tumor 194 
samples and cell lines than in control tissues and cell lines and that its elevated 195 
expression is involved in BL lymphomagenesis (10). To investigate the mechanisms 196 
implicated in E2F1 deregulation in BL, we compared E2F1 mRNA stability in BL and 197 
immortalized, but non-transformed, Lymphoblastoid B-cell lines (LCL). Transcription 198 
was blocked in these cells with actinomycin D before assessing RNA expression by 199 
qPCR analyses. We found no major differences in reduction of E2F1 mRNA levels 200 
between BL and LCL cell lines following transcription inhibition (Figure 1A). Since 201 
these results suggested that E2F1 mRNA half-life was similar in BL and LCL cell lines, 202 
we investigated whether its promoter was more active in BL than in control cell lines. 203 
Firefly luciferase reporter plasmids driven by a wild-type (wt) human E2F1 promoter 204 
were transfected in different BL and LCL cell lines. For normalization, Renilla 205 
luciferase or ß-galactosidase reporter plasmids under the control of the SV40 promoter 206 
or the CMV promoter, respectively, were cotransfected. The normalized activity of the 207 
wt E2F1 promoter was 10-100 times higher in BL than in LCL cell lines when either 208 
Renilla luciferase (Figure 1B) or ß-galactosidase (Figure S1) were used as reference. 209 
The E2F1 promoter contains two E2F binding elements (Figure 1C) that negatively 210 
regulate its activity in fibroblasts (24). We compared the activity of the wt E2F1 211 
promoter with that of a modified version (mut) with inactivated E2F elements in both 212 
BL and LCL cell lines. The activity of the mut version was higher than that of the wt 213 
version in LCL cell lines (Figure 1D), thus suggesting that these E2F elements play a 214 
repressor role in these cells. In contrast, the activities of wt and mut versions of the 215 
E2F1 promoter were almost identical in BL cell lines (Figure 1D), indicating that these 216 
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E2F sites lacked repressor activity in these cells. Together, these data suggest that the 217 
higher expression of E2F1 in BL relative to LCL cell lines might be due to impaired 218 
transcriptional repression through the E2F elements from the E2F1 promoter in BL 219 
cells. 220 
BL and LCL cells show different DNA-protein complex formation patterns. 221 
To investigate whether differences in E2F1 promoter repression between BL and LCL 222 
cell lines might be caused by differences in the set of proteins that interact with the E2F 223 
elements, we compared the pattern of protein-DNA complex formation between a 224 
radiolabeled oligonucleotide corresponding to the distal E2F element from the E2F1 225 
promoter (E2F1-d) and nuclear extracts from BL and LCL cell lines. Several groups, 226 
including ours, have described the formation of 4 major retarded complexes between 227 
E2F sites and nuclear extracts from several cell types, including LCL cell lines (26, 28, 228 
29). These complexes contained E2F associated to p107 and p130 (complex I), E2F 229 
bound to pRB (complex II), and either E2F4 (complex III) or E2F5 (complex IV) ‘free’ 230 
from association with pRB family members (26, 28, 29). Accordingly, the interaction of 231 
nuclear extracts from various LCL cell lines and the labeled E2F1-d probe gave rise to 4 232 
major retarded complexes (Figure 2A) whose formation was inhibited by an excess of 233 
the same unlabeled oligonucleotide (Figure 2B). Remarkably, complex III formation 234 
was barely detected when nuclear extracts from BL cell lines were employed (Figures 235 
2A and S2). Formation of complexes I-IV was affected by addition of antibodies against 236 
various E2F and pRB family members (Figures 2C, 2D and S2). In particular, formation 237 
of complexes I and III was inhibited by addition of antibodies against DP1 and E2F4 238 
subunits when nuclear extracts from LCL cell lines were employed (Figures 2D and 239 
S2). Of note, anti-E2F4 antibodies barely inhibited complex I formation when nuclear 240 
extracts from BL cell lines were used, but its formation was impaired by addition of 241 
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antibodies to DP1, p107 or p130 (Figures 2C and S2). These results suggested that 242 
either E2F4 from BL lost its capacity to interact with DNA or that it was almost absent 243 
in these cells. 244 
E2F4 is downregulated in sBL.  245 
We compared E2F4 levels in BL and LCL cell lines by immunoblotting and found that 246 
E2F4 expression was markedly lower in BL (Figure 3A). In contrast, E2F4 mRNA 247 
levels were similar in both cell types (Figure 3B). Hence, E2F4 protein expression 248 
down-regulation in BL cells is not caused by decreased mRNA expression. To ascertain 249 
whether protein stabilization was involved in differences in E2F4 expression between 250 
these cell types, we analyzed the effect of translation inhibition with cycloheximide on 251 
its expression. We found that E2F4 half-life was markedly shorter in BL than in control 252 
cell lines (Figure 3C).  253 
We next used immunohistochemistry to compare E2F4 protein levels in control 254 
tissues and a collection of 26 biopsy sBL specimens that met the combined 255 
morphological, immunohistochemical and cytogenetic criteria for BL according to the 256 
WHO classification. We used germinal centres of reactive tonsils as control tissues 257 
because they are formed almost exclusively by proliferating B cells. We employed 258 
qPCR (Figures 4A and S3A) or immunohistochemistry (Figure S3B) to confirm that 259 
E2F1 expression was increased in these samples relative to control tissues. As expected 260 
in asynchronously growing cells, E2F4 was readily detected in the nucleus and cytosol 261 
of most cells in the germinal center of reactive tonsils (Figure 4). E2F4 levels were 262 
much lower in 20 sBL specimens (Figure 4A), moderately lower in four additional 263 
samples (Cases 5, 13, 21, and 22; Figure 4A) and relatively normal only in Cases 2 and 264 
14. Of note, E2F4 location was mostly cytosolic in numerous cells of Case 13 (Figure 265 
4). Hence, E2F4 levels or location were altered in 24 of 26 sBL samples (92.3 %). We 266 
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determined E2F4 mRNA expression in 23 of these sBL specimens and found that it was 267 
similar to that observed in the control tissues (Figure S4). Hence, in accordance with 268 
our results using cell lines, E2F4 downregulation in sBL samples was not due to 269 
reduced mRNA expression levels.  270 
Since E2F4 negatively regulates E2F1 transcription in concert with p130 (30, 271 
31), we hypothesized that p130 expression might be downregulated in BL tumor 272 
samples with relatively normal E2F4 levels. To address this issue, we used 273 
immunohistochemistry to analyze its expression in these samples. While p130 was 274 
readily detected in the nucleus of most cells in germinal centers of reactive tonsils, it 275 
was almost undetectable in the sBL cases herein studied (Figure 5A). However, its 276 
expression was similar in BL and LCL cell lines (Figure 5B), suggesting that these cell 277 
lines are not valid to assess p130 role in BL formation. We also assessed E2F4 and p130 278 
levels in 67 DLBCL specimens and found that, as opposed to sBL, most Cases were 279 
positive for both proteins (Table SI). Together, our data suggest that the E2F4-p130 axis 280 
is downregulated in most sBL cases included in our study, but not in DLBCL. 281 
E2F4 regulates E2F1 expression and BL tumor formation. 282 
Our results suggest that down-regulation of the E2F4-p130 pathway in sBL cells 283 
might hamper repression of the E2F1 promoter, thus leading to E2F1 overexpression in 284 
these cells. According to this hypothesis, forced expression of E2F4 in these cells 285 
should reduce E2F1 levels. To confirm it, three BL cell lines (DG75, Ramos, and Mutu-286 
I) were transduced with a retrovirus encoding E2F4 employing conditions that rendered 287 
E2F4 levels similar to those present in control cells (Figure S5). Protein expression was 288 
determined in transduced cells following puromycin selection. We found that ectopic 289 
E2F4 caused a sharp reduction of E2F1 protein levels without affecting those of Tubulin 290 
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(Figure 6A). Accordingly, E2F1 mRNA expression, but not that of GAPDH, decreased 291 
in DG75 cells transduced with E2F4 (Figure S6). 292 
BL cell lines produce malignant tumors in immunodeficient mice (32). We have 293 
shown that tumors formed by inoculation of BL cell lines, such as DG75 or Ramos, into 294 
these mice are solid masses consisting of tumor lymphoid cells (10). To investigate 295 
whether deregulation of the E2F4-p130 pathway is involved in BL tumor formation in 296 
vivo, we enforced E2F4 expression in BL cell lines by retroviral transduction. The 297 
capacity of these cells to form tumors was subsequently determined through their 298 
inoculation into immunodeficient mice. DG75, Ramos, and Mutu-I cells transduced 299 
with a mock retrovirus elicited formation of tumors >0.3g in mass within three weeks 300 
(Figure 6B). In contrast, mice inoculated with BL cell lines transduced with retroviruses 301 
encoding E2F4 formed no tumors or very small tumors (Figure 6B). Therefore, E2F4 302 
over-expression in BL cells severely inhibited their tumor formation capacity, thus 303 
pointing to E2F4 as a key player in BL lymphomagenesis. 304 
E2F4 inhibits proliferation and elicits G2/M accumulation of BL cells.  305 
To investigate the mechanism of tumor formation inhibition by E2F4, we 306 
compared cell proliferation rates of BL cell lines (DG75, Ramos, and Mutu-I) with 307 
normal or augmented E2F4 levels. We found that BL cells that overexpress E2F4 308 
incorporated 5-fold less [3H]dThd than mock-transduced cells (Figure 7A). Remarkably, 309 
E2F4 overexpression in a breast carcinoma cell line (MCF-7) or in a fibroblast cell line 310 
(NIH-3T3) barely affected E2F1 levels and did not inhibit their proliferation (Figures 311 
7B-7C), suggesting that E2F4 levels were not a limiting factor for E2F1 expression and 312 
cell growth regulation in these cells. 313 
C-MYC overexpression in normal cells arrests them in the G2 phase of the cell 314 
cycle (9) and E2F1 knock-down in sBL cells leads to their accumulation in G2/M (10). 315 
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Since E2F1 levels are drastically reduced in BL cells that overexpress E2F4, we 316 
hypothesized that these cells might also be arrested in G2/M. Cell cycle distribution 317 
analysis of mock- and E2F4-transduced cells revealed that 26% of mock-transduced BL 318 
cells were found in G2/M, whereas >38% of E2F4-transduced BL cells accumulated in 319 
G2/M (Figures 7D-7E). Accordingly, the amount of cells in G0/G1 and S was reduced in 320 
BL cells that over-expressed E2F4 compared to control cells (Figures 7D-7E). These 321 
results were similar to those obtained with BL cells expressing an shRNA specific for 322 
E2F1 (Figures 7D). Together, our results indicate that enforced E2F4 expression in BL 323 
cells reduces their proliferation capacity and leads to their accumulation in the G2/M 324 
phase of the cell cycle.  325 
326 
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DISCUSSION 327 
The identification of molecular hits leading to sBL formation may facilitate the 328 
development of more specific, less toxic therapies than those currently in use. 329 
Unfortunately, the pathways underlying sBL formation are not completely understood. 330 
We have reported recently that E2F1 was overexpressed in 100% of the sBL cases 331 
studied and that its overexpression was required for tumor formation (10). We have now 332 
investigated the mechanisms deregulating E2F1 levels in BL and found that the 333 
transcriptional repression pathway mediated by E2F4 is down-regulated in BL cell lines 334 
and sBL tumor samples relative to control cell lines and tissues and that this defect is 335 
critical for E2F1 deregulation in this tumor and for lymphomagenesis.  336 
These results are seemingly in conflict with a previous report showing that the 337 
absence of E2f4 delays tumor onset in an Eµ-myc mouse model (33). There is no 338 
conflict, however, because while the Eµ-myc mouse is useful to study the role of c-myc 339 
in lymphomagenesis (34), this mouse is not a BL model. Indeed, Eµ-myc mice develop 340 
primarily pre-B cell tumors whose histopathologic features are consistent with the 341 
diagnosis of lymphoblastic lymphoma rather than BL (35).   342 
Since we found that E2F1 mRNA stability was similar in BL and control cells 343 
and that the E2F1 promoter was more active in BL than in control cells, we propose that 344 
deregulation of this promoter accounts for the elevated expression of E2F1 in BL. This 345 
promoter contains two E2F-binding sites that repress its transcription in immortalized 346 
fibroblasts (24). Accordingly, we found that these sites also act as transcriptional 347 
repressors in immortalized B-cell lines. Remarkably, these sites failed to repress E2F1 348 
transcription in BL cells likely because E2F4 expression was down-regulated in these 349 
cells. Indeed, restoration of relatively normal E2F4 level in BL cells reduced E2F1 350 
expression. However, we cannot rule out that additional mechanisms might also 351 
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facilitate E2F1 deregulation, including C-MYC-mediated activation of CDKs (36) or 352 
the existence of a positive feedback loop mediated by E2F1. 353 
Since E2F4 is the most abundant E2F family member (17), its reduced levels in 354 
BL cells might readily increase E2F1 expression in them. Although other repressor E2F 355 
factors could potentially inhibit E2F1 transcription, only E2F4 levels were markedly 356 
lower in BL than in control cells. Indeed, E2F2, E2F3, E2F5, and E2F6 expression was 357 
similar in both cell types [(10) and Figure S7] and E2F7 was undetectable in these cells 358 
(our unpublished observations). Of note, E2F8 mRNA levels were higher in BL than in 359 
LCL cells (Figure S7). E2F1 binds and activates the E2F8 promoter whereas E2F8 360 
binds and repress the E2F1 promoter (37). Therefore, E2F1 deregulation might account 361 
for a higher expression of E2F8 in BL cells. Whether E2F8 down-modulation in these 362 
cells would further increase E2F1 expression remains to be elucidated. Finally, enforced 363 
E2F4 expression in BL cells decreased E2F1 levels. Therefore, even if E2F4 is not the 364 
only repressor E2F family member that modulates E2F1 transcription in other cell 365 
settings, its downregulation in BL is likely responsible of E2F1 overexpression in this 366 
tumor. This regulatory mechanism might be common to other tumors, such as anaplastic 367 
thyroid cancers, in which E2F1 and E2F4 expression are also inversely regulated (38). 368 
E2F4 has a transactivation domain and activates transcription and gene 369 
expression in certain scenarios (39, 40). Its transcriptional activity is restrained by 370 
interaction with pocket proteins. Moreover, E2F4 binding to pRB family members is 371 
required for its repressor role (41). In particular, recruitment of E2F4/p130 complexes to 372 
the E2F sites in the E2F1 promoter is critical for E2F1 transcriptional repression (30, 373 
42). In addition, the presence of strong nuclear export signals in E2F4 can promote its 374 
cytosolic location and thus restrain its transcriptional activity (11, 20). Since E2F4 375 
levels were lower in most sBL biopsy specimens herein studied than in control tissues, 376 
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we propose that E2F1 expression is deregulated in these cases through a defect in 377 
transcriptional repression. E2F4 levels were similar or only moderately lower to those 378 
of control tissues in only 2 and 3 samples, respectively, of 26 specimens and might, 379 
therefore, activate or repress E2F1 expression in these samples. Because p130 was 380 
almost undetectable in these biopsy specimens, it seems likely that E2F4 might not be 381 
able to repress E2F1 transcription in these cases. In one additional sample (case 13), 382 
E2F4 levels were similar to those of control tissues, but its location was mostly 383 
cytosolic in most cells, thus arguing against a transcriptional repressor activity of E2F4 384 
in this sample. Together, our findings strongly support that E2F4 might be unable to 385 
repress E2F1 transcription in sBL tumor samples.   386 
 A recent study documenting expression profiles of BL samples and germinal 387 
center cells revealed that they were intimately related, differing for molecules involved 388 
in cell proliferation, immune response, and signal transduction (43). E2F4 was not 389 
among the genes deregulated in BL relative to normal cells. Accordingly, we detected 390 
no differences in E2F4 mRNA expression between BL and control cell lines. These 391 
results raise the possibility that E2F4 level is regulated post-transcriptionally in sBL 392 
samples. Indeed, our findings revealed that differences in protein stabilization likely 393 
account for E2F4 deregulated expression in BL.  394 
E2F1 and E2F4 are proteolyzed through the ubiquitin-proteasome pathway and 395 
their binding to pRB family members protects them from degradation (23, 44-46). Since 396 
p130 is one of the major partners of E2F4 and its expression is downregulated in some 397 
of our sBL cases, E2F4 might be destabilized in BL relative to control tissues because 398 
of the low abundance of p130. However, p130 expression was similar in BL and LCL 399 
cell lines. We have also sequenced E2F4 cDNA from 3 BL cell lines and found no 400 
single mutation in its coding sequence (our unpublished obervations), thus ruling out 401 
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that its decreased protein stability is due to mutations. Instead, unidentified yet 402 
posttranslational modifications might perhaps facilitate its ubiquitilation and 403 
proteolysis. Additional research is required to uncover these modifications.   404 
E2F4 is generally considered as an inhibitor of cell proliferation. Accordingly, 405 
our results support a negative role for E2F4 in BL cell proliferation. However, 406 
accumulating evidence suggest that E2F4 can also activate cell proliferation in certain 407 
contexts, such as fetal erythropoiesis (47), heart development (48), or colon epithelium 408 
homeostasis (49). Hence, E2F4 plays a dual role in proliferation regulation that might 409 
depend on cell context or the expression level of other E2F family members. 410 
The hallmark of BL cells is the reciprocal translocation between one of three 411 
immunoglobulin gene loci and the C-MYC gene that leads to deregulated C-MYC 412 
expression (50). This translocation is not the only critical event in BL pathogenesis (7). 413 
Indeed, C-MYC overexpression alone cannot sustain proliferation of normal cells but, 414 
instead, either arrests them in G2 (9) or leads them to undergo apoptosis (8). Additional 415 
hits should therefore be involved in the biology of BL. In this regard, we have shown 416 
previously that elevated E2F1 expression in BL cells might facilitate their escape from 417 
C-MYC-induced G2 arrest (10). We show now that E2F4 down-regulation in these cells 418 
might also facilitate their escape from C-MYC-induced G2 arrest and their capacity to 419 
form tumors. Together, our results strongly support that insufficient E2F4 levels in BL 420 
cells might cause elevated E2F1 expression and, hence, enable them to overcome C-421 
MYC-induced growth arrest and to form tumors. Therefore, E2F4 is a potential target for 422 
therapeutic intervention in BL. Drugs or compounds that inhibit its proteolysis, such as 423 
Bortezomib, might restore normal E2F4 levels in BL cells and inhibit their growth. A 424 
better characterization of the mechanisms involved in E2F4 proteolysis in BL might 425 
provide more specific therapeutic tools. 426 
427 
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FIGURE LEGENDS 591 
Figure 1. Different E2F1 transcription rates account for different E2F1 mRNA 592 
expression levels in sBL and LCL cell lines. (A) Representative qPCR analysis of E2F1 593 
levels in the indicated cell lines after actinomycin D (10 µg/ml) treatment during the 594 
indicated periods of time. Expression is shown relative to non-treated cells (0h) and 595 
normalized by β-ACTIN. (B) A firefly luciferase reporter plasmid containing the E2F1 596 
promoter was co-transfected with pRL-SV40 into the indicated cell lines. Firefly luciferase 597 
activity is shown relative to Renilla luciferase activity for each cell line. The average and 598 
SD of four independent experiments is shown. *P<0.05, **P<0.01 and ****P<0.0001 vs 599 
X50-7.  (C) Schematic representation of the E2F1 promoter indicating the proximal and 600 
distal E2F sites in close proximity to the transcription start site. (D) Luciferase reporter 601 
plasmids containing wt or mutated E2F sites from the E2F1 promoter were co-transfected 602 
with pRL-SV40 into the indicated cell lines. Firefly luciferase values were normalized by 603 
Renilla activity. Normalized luciferase values for the mutant reporter (solid columns) are 604 
shown relative to those of the wt reporter (empty columns) in the indicated cell lines as 605 
average + SD of four independent experiments. ***P<0.005 vs wild-type.  606 
Figure 2. Analysis of DNA-binding species that interact with the distal E2F element 607 
within the E2F1 promoter reveals a different binding pattern in BL and LCL cells. 608 
(A) Complex formation employing nuclear extracts from the indicated cell lines and 609 
radiolabeled distal E2F element from the E2F1 promoter (E2F1-d) was analyzed by 610 
EMSA. Reaction mixtures were pre-incubated in the absence (-) or in the presence (+) of a 611 
50-fold excess of the unlabeled oligonucleotide (B) or in the presence of Abs against the 612 
indicated proteins (C - D) for 20 min prior to addition of the labeled probe. A DP1 pre-613 
immune rabbit polyclonal Ab was used as control. The position of complexes I-IV is 614 
indicated. Free probes are not shown to do not unnecessarily enlarge figures size.  615 
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Figure 3. E2F4 shows lower expression levels and protein stability in BL than in LCL 616 
cells. (A) Representative immunoblotting of four analysis performed of E2F4 and tubulin 617 
protein expression in the indicated cell lines. (B) qPCR analysis of E2F4 mRNA 618 
expression in the indicated cell lines. Expression is shown relative to that found in the LCL 619 
cell line IB4 and normalized by β-actin. Columns, average (n=3); bars, SD. (C) 620 
Representative immunoblotting of three analysis performed of E2F4 and tubulin protein 621 
expression in the indicated cell lines treated with 100 µg/ml cycloheximide during the 622 
indicated times.  623 
Figure 4. E2F4 expression is downregulated in sBL biopsy specimens. (A) E2F1 and 624 
E2F4 expression were assessed by qPCR and immunohistochemistry, respectively, in a 625 
reactive tonsil and the indicated sBL tumor samples. E2F1 levels are shown relative to the 626 
control tissue. +, <2 fold; ++, 5-10 fold; +++, 10-15 fold; ++++, >15 fold (see also Figure 627 
S3A). POS, Cases that could no be analyzed by qPCR, but were positive for E2F1 628 
immunohistochemistry staining (see also Figure S5). E2F4 levels were determined by 629 
immunohistochemistry. 0, No positive cells; +, 0-30% positive cells and/or low level; ++, 630 
30-70% positive cells; +++, >70% positive cells; C, Cytosolic staining in most cells. (B) 631 
Representative images of E2F4 staining of a reactive tonsil (section of a germinal centre) 632 
and the indicated sBL cases. Please, note that despite morphology of Case 1, the rest of its 633 
phenotypical and cytogenetic characteristics are typical of BL. Scale bar, 10 µm. 634 
Figure 5. The expression of p130 is down-regulated in sBL biopsy specimens. (A) 635 
Representative images of p130 staining of a reactive tonsil (section of a germinal centre) 636 
and the indicated sBL cases. Scale bar, 10 µm. (B) Representative immunoblotting of three 637 
analysis performed of E2F4 and tubulin protein expression in the indicated cell lines. 638 
Figure 6. E2F4 inhibits E2F1 expression and tumor formation. DG75, Ramos, and 639 
Mutu-I BL cell lines were transduced with retroviruses bearing an empty expression vector 640 
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(mock) or an E2F4 expression vector (HA-E2F4). (A) Representative immunoblotting of 641 
four experiments performed with the indicated antibodies. (B) Weight of tumors extracted 642 
from immunodeficient mice inoculated with the indicated cells (n=7, n=12 and n=5 for 643 
DG75, Ramos and Mutu-I, respectively).  644 
Figure 7. E2F4 reduces cell proliferation and elicits G2/M accumulation in BL cells. 645 
(A) DG75, Ramos and Mutu-I cells or (B) MCF-7 and NIH-3T3 cells were transduced with 646 
retroviruses bearing an empty expression vector (mock) or an E2F4 expression vector (HA-647 
E2F4). (A) [3H]dThd incorporation in DG75 cells are shown relative to mock-transduced 648 
cells as average + SD of four independent experiments performed in triplicate. 649 
****P<0.0001 vs mock. (B) Representative immunoblotting of three analyses performed 650 
with the indicated antibodies. (C) Edu incorporation in these cells is shown relative to 651 
mock-transduced cells as average + SD of three independent experiments performed in 652 
triplicate. (D) Representative cell cycle profiles of DG75 cells transduced with retroviruses 653 
bearing an empty expression vector (mock), an E2F4 expression vector (HA-E2F4), or 654 
DG75 cells transduced with lentiviruses encoding a shRNA specific for E2F1 (E2F1-655 
shRNA). G2-M phase of the cell cycle is indicated (arrowhead). (E) Columns, average (n = 656 
4) of the percentage of each of the indicated transduced cells in G0-G1, S, and G2-M; bars, 657 










Supplemental Figure 1. Increased E2F1 promoter activity in BL. A firefly luciferase 
reporter plasmid containing the E2F1 promoter was co-transfected with pCMV-βgal into 
the indicated cell lines. Firefly luciferase activity is shown relative to ß-galactosidase 
activity. The average and SD of four independent experiments is shown. ****P<0.0001 vs 
X50-7. 
Supplemental Figure 2. Analysis of DNA-binding species that interact with the distal 
E2F element within the E2F1 promoter. Complex formation employing nuclear extracts 
from DG75 (BL) and JY (LCL) cell lines and radiolabeled distal E2F element from the 
E2F1 promoter was analyzed by EMSA. Reaction mixtures were pre-incubated in the 
presence of Abs against the indicated proteins for 20 min prior to addition of the labeled 
probe. A DP1 pre-immune rabbit polyclonal Ab was used as control. The position of 
complexes I-IV is indicated. Free probes are not shown to do not unnecessarily enlarge 
figures size.  
Supplemental Figure 3. Analysis of E2F1 expression in sBL tumor samples. (A) 
qPCR analysis of E2F1 mRNA levels in the indicated sBL cases and reactive tonsils is 
shown relative to that found in reactive tonsil 1 and normalized by β-actin. Columns, 
average (n = 3); bars, SD. (B) Representative images of E2F1 immunohistochemistry 
staining of a reactive tonsil (section of a germinal centre) and the indicated sBL cases 
are shown. Scale bar, 10 µm. 
Supplemental Figure 4. Analysis of E2F4 expression in sBL tumor samples. qPCR 
analysis of E2F4 mRNA levels in the indicated sBL cases and reactive tonsils is shown 
relative to that found in reactive tonsil 1 and normalized by β-actin. Columns, average 
(n = 3); bars, SD.  
Supplemental Figure 5. E2F4 inhibits E2F1 expression in BL cells. Ramos and 
DG75 BL cell lines were transduced with retroviruses bearing an empty expression 
vector (mock) or an E2F4 expression vector (E2F4). Immunoblotting performed with 
the indicated antibodies is shown. X50-7 and JY (LCL cell lines) and BL2 (BL cell line) 
are shown as controls. 
Supplemental Figure 6. E2F4 inhibits E2F1 transcription in BL. DG75 cells were 
transduced with retroviruses bearing an empty expression vector (mock) or an E2F4 
expression vector (HA-E2F4). qPCR analysis of E2F1 and GAPDH mRNA levels in these 
cells is shown relative to that found in mock-transduced cells and normalized by β-actin. 
Columns, average (n = 3); bars, SD. ****P<0.0001 vs mock. 
Supplemental Figure 7. Analysis of E2F5, E2F6 and E2F8 expression in BL and LCL 
cell lines. Representative immunoblotting of three analysis performed of E2F5 (A) and 
E2F6 (B) protein expression in the indicated cell lines. Tubulin is shown as loading control. 
(C) qPCR analysis of E2F8 mRNA expression in the indicated cell lines. Expression is 
shown relative to that found in the LCL cell line IB4 and normalized by β-actin. Columns, 




Case E2F1 E2F4 P130 
1 + +++ +++ 
2 0 +++ +++ 
3 + +++ +++ 
4 0 ++ +++ 
5 + +++ +++ 
6 0 +++ +++ 
7 0 0 0 
8 0 ++ +++ 
9 0 +++ +++ 
10 +++ ++ +++ 
11 0 +++ +++ 
12 0 +++ +++ 
13 + +++ +++ 
14 +++ +++ + 
15 + +++ +++ 
16 0 +++ 0 
17 ++ +++ +++ 
18 + +++ 0 
19 + 0 +++ 
20 0 +++ +++ 
21 0 +++ +++ 
22 0 +++ +++ 
23 +++ +++ +++ 
24 + +++ +++ 
25 0 +++ +++ 
26 + +++ +++ 
27 +++ +++ +++ 
28 0 +++ +++ 
29 +++ +++ +++ 
30 ++ +++ +++ 
31 ++ +++ +++ 
32 + ++ +++ 
33 ++ +++ ++ 
34 0 +++ +++ 
35 0 +++ +++ 
36 0 +++ ++ 
37 0 +++ +++ 
38 0 + + 
39 0 +++ +++ 
40 + ++ 0 
41 n.d. +++ 0 
42 + +++ +++ 
43 0 ++ +++ 
44 ++ +++ +++ 
45 0 + 0 
46 + n.d. +++ 
47 0 0 ++ 
48 ++ C +++ 
49 0 +++ +++ 
50 0 0 +++ 
51 + +++ +++ 
52 0 0 ++ 
53 0 +++ 0 
54 0 +++ 0 
55 + +++ +++ 
56 + +++ ++ 
57 + ++ + 
58 0 +++ +++ 
59 +++ +++ +++ 
60 ++ +++ +++ 
61 ++ +++ +++ 
62 + +++ +++ 
63 0 + 0 
64 0 +++ +++ 
65 ++ +++ +++ 
66 0 + + 
67 + +++ +++ 
 
Supplemental Table 1. Assesment of E2F1, E2F4 and p130 expression in DLBCL 
cases. E2F1, E2F4 and p130 expression were assessed by immunohistochemistry in the 
indicated DLBCL tumor samples. 0, No positive cells; +, 0-30% positive cells and/or 
low level; ++, 30-70% positive cells; +++, >70% positive cells; C, Cytosolic staining in 
most cells; n.d., not determined. 
 
 







